Marc B. Garnick, MD, presented “Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.
How to cite: Garnick, Marc B. “Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors.” January 24, 2023. Accessed Nov 2024. https://grandroundsinurology.com/vitamin-d-and-mens-health/
Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors – Summary
Marc B. Garnick, MD, Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, reviews current literature on the treatment of prostate cancer. Dr. Garnick focuses specifically on Androgen Deprivation Therapy (ADT,) Chemotherapy, Androgen Receptor Inhibitors, and Androgen Synthesis Inhibitors.
In this presentation, Dr. Garnick explores:
- The current landscape of Advanced Prostate Cancer Treatments
- The use of triplet therapies in combating metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- The possibility of avoiding ADT by combining advanced imaging techniques with Metastasis-Directed Therapy (MDT)
About The 33rd Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.
ABOUT THE AUTHOR
Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where he also directs the hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has dedicated his career to the development of new therapies for prostate cancer. He serves as the Editor-in-Chief for The Annual Report on Prostate Diseases, formerly Perspectives on Prostate Disease. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron). In addition to his academic affiliations, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research at Beth Israel Deaconess Medical Center, serves as medical adviser to World Book Encyclopedia, and is an active advisory member of several FDA panels and advisory committees. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and of Penn Medicine. Dr. Garnick is also a Trustee Emeritus of Bowdoin College in Brunswick, Maine.
